



6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.202.1401
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

Data Sheet
Spike (SARS-CoV-2, D614G)
Pseudotyped Lentivirus (Luc Reporter)
Catalog#: 78028

Product Description

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic.

The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.

Application

1. Study the mechanism of viral transduction.
2. Screening for neutralizing antibodies for SARS-CoV-2 Spike and ACE2.

Formulation

The lentiviruses were produced from HEK293T cells in medium containing 90% DMEM + 10% FBS.

Titer

The titer will vary with each lot; the exact value is provided with each shipment.

Biosafety

None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com




Figure 1. Schematic of the Luciferase Reporter in SARS-CoV-2 Spike Pseudovirion Storage

Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C . Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Materials Required but Not Supplied

- Thaw Medium 1 (BPS Bioscience #60187): MEM with 10% FBS, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate
- ACE2-HEK293 Recombinant Cell Line (BPS Bioscience, #79951)
- Anti-SARS-CoV-2 Spike neutralizing antibody (BPS Bioscience, #100793)
- 96-well tissue culture treated, white clear-bottom assay plate (Corning, #3610)
- ONE-Step™ luciferase assay system (BPS Bioscience, #60690)

Assay Protocol

The following protocol is a general guideline for transducing ACE2-HEK293 cells using SARS-CoV-2 Spike D614G pseudotyped lentivirus (Luciferase reporter). The optimal transduction conditions (e.g. MOI, concentration of polybrene, time of assay development) should be optimized according to the cell type and the assay requirements. In most cell types, the expression of the reporter gene can be measured approximately 48-72 hours after transduction.

1. Day 1: Harvest ACE2-HEK293 cells from culture and seed cells at a density of 5,000-10,000 cells per well into white opaque 96-well microplate in 50 μl of Thaw Medium 1 (BPS Bioscience, #60187). Incubate cells at 37°C with 5% CO_2 overnight.

To demonstrate transduction is dependent on ACE2, the same number of HEK293 parental cells are seeded in Thaw Medium 1 as control cells.

2. Day 2: prepare serial dilutions of anti-Spike or anti-ACE2 antibody in Thaw Medium 1.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com



6042 Cornerstone Court W, Ste B
San Diego, CA 92121
Tel: 1.858.202.1401
Fax: 1.858.481.8694
Email: info@bpsbioscience.com

To test anti-Spike antibody, preincubate 5 μ l of the SARS-CoV-2 Spike D614G pseudotyped lentivirus with 5 μ l of diluted anti-Spike antibody for 30 minutes. After incubation, add 10 μ l of virus/antibody mix into each well of the ACE2-HEK293 cells.

To test anti-ACE2 antibody, add 5 μ l of diluted anti-ACE2 antibody into each well of ACE2-HEK293 cells and incubate for 30 minutes. At the end of the incubation, add 5 μ l of SARS-CoV-2 Spike D614G pseudotyped lentivirus into each well.

For control wells, the same number of ACE2-HEK293 cells are seeded, but no virus or antibody are added.

Incubate the plates at 37°C with 5% CO₂ overnight.

Alternatively, seeding cells and the transduction can be performed on the same day.

3. Day 3: Remove the medium containing the lentivirus from the wells. Add 50 μ l of fresh Thaw Medium 1 to each well.

If the tested antibody does not adversely affect the target cells, it is not necessary to change the medium on Day 3.

4. Day 4, approximately 48-60 hours after transduction, prepare the ONE-Step™ Luciferase reagent per recommended protocol. Add 50 μ l of ONE-Step™ Luciferase Assay reagent per well. Incubate at room temperature for ~15 to 30 minutes and measure luminescence using a luminometer. The transduction efficacy is determined by measuring the luciferase activity.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.
To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**
Or you can Email us at: info@bpsbioscience.com
Please visit our website at: www.bpsbioscience.com




Figure 2. Transduction of ACE2-HEK293 Cells using SARS-CoV-2 Spike D614G Pseudotyped Lentivirus.

A. Approximately 10,000 cells/well of ACE2-HEK293 cells or HEK293 parental cells were transduced with 5 μ l/well of SARS-CoV-2-Spike D614G pseudotyped lentivirus (Luc reporter) (BPS Bioscience #78028). After 18 hours of transduction, the medium was changed to fresh HEK growth medium (Thaw Medium 1). After 48 hours of transduction, ONE-Step Luciferase reagent (BPS Bioscience, #60690) was added to cells to measure the luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus transduced ACE2-HEK293 cells with much greater efficiency compared with HEK293 parental cells, indicating the transduction is dependent upon ACE2 expression.

B. Approximately 10,000 ACE2-HEK293 cells/well were transduced with 10 μ l/well of SARS-CoV-2 Spike pseudotyped lentivirus (Luc reporter) mixed with anti-Spike antibody (BPS Bioscience #100793). After 18 hours of transduction, the medium was changed to fresh HEK growth medium (Thaw Medium 1). After 48 hours of transduction, ONE-Step Luciferase reagent (BPS Bioscience #60690) was added to cells to measure the luciferase activity.

Related Products

<u>Product</u>	<u>Cat. #</u>	<u>Size</u>
Spike Pseudotyped Lentivirus (Luciferase Reporter)	79942	500 μ l x2
Bald Lentiviral Pseudovirion (Luciferase Reporter)	79943	500 μ l x2
Spike Pseudotyped Lentivirus (eGFP Reporter)	79981	500 μ l x2
Bald Lentiviral Pseudovirion (eGFP Reporter)	79987	500 μ l x2
Spike Pseudotyped Lentivirus (Luciferase-eGFP Dual Reporter)	79982	500 μ l x2
Bald Lentiviral Pseudovirion (Luciferase-eGFP Dual Reporter)	79988	500 μ l x2
eGFP Lentivirus	79979	500 μ l x2
Firefly Luciferase-eGFP Lentivirus	79980	500 μ l x2
Negative Control Lentivirus	79578	500 μ l x2
Renilla Luciferase (Rluc) Lentivirus	79565	500 μ l x2
Firefly Luciferase (Fluc) Lentivirus	79692	500 μ l x2

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

To place your order, please contact us by Phone **1.858.202.1401** Fax **1.858.481.8694**

Or you can Email us at: info@bpsbioscience.com

Please visit our website at: www.bpsbioscience.com